NCT01226030

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Protgen Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

Detailed description

This study is a Phase I dose-escalation open-label study to determine the MTD of M2ES in Subjects With Advanced Solid Tumors the recommended Phase II dose.The recommended dose and regimen of M2ES will be selected to perform the pharmacokinetic study profiles.

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	M2ES 7.5mg	M2ES 7.5mg
DRUG	M2ES 15mg	M2ES 15mg
DRUG	M2ES 30mg	M2ES 30mg
DRUG	M2ES 60mg	M2ES 60mg

Timeline

• Start date: 2009-09-01
• Primary completion: 2011-04-01
• Completion: 2011-06-01
• First posted: 2010-10-21
• Last updated: 2010-10-21

Locations

1 site across 1 country: China